Coherus Biosciences Stock News

Coherus BioSciences press release (CHRS): Q4 Non-GAAP EPS of -$0.46 beats by $0.08.Revenue of $73.37M (-33.6% Y/Y) misses by $9.24M.Cash and cash equivalents were $417.2 million as…

– YUSIMRY ™ (adalimumab-aqvh), Coherus’ second product, approved by FDA on December 17, 2021 – – BLAs under FDA review for PD-1 inhibitor toripalimab and CIMERLI ™ (ranibizumab-ranq) – – New FDA filings expected in 2022 for UDENYCA ® on-body injector and additional toripalimab indications – – UDENYCA ® delivered net sales of $73 million in 4Q 2021; $327 million in FY 2021 – – Conference call and webcast today at 5:00 p.m. ET –

Coherus BioSciences (CHRS) delivered earnings and revenue surprises of 1.64% and 11.94%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Coherus BioSciences (NASDAQ:CHRS) is scheduled to announce Q4 earnings results on Thursday, February 17th, after market close.The consensus EPS Estimate is -$0.54 (compared to $0.23 in…

REDWOOD CITY, Calif., Feb. 11, 2022 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that its fourth quarter and full year 2021 financial results will be r

Coherus Biosciences <> is set to close lower after JPMorgan analyst Christopher Schott slashed his price target on the biotech to $20 from $23 per share to imply a premium of ~62%

The COHERUS BIOSCIENCES POLITICAL ACTION COMMITTEE successfully filed their F3XN QUATERLY YEAR-END with the coverage period of 10/01/2021 to 12/31/2021 and a confirmation ID of FEC-1564749 *********CommitteeId: C00789370 | FilingId: 1564749 | FormType: F3XN | CoverageFrom: 10/01/2021 | CoverageThrough: 12/31/2021 | ReportType: QUATERLY YEAR-END*********

Coherus and Junshi Biosciences plan to evaluate the toripalimab + JS006 combination in clinical trials in multiple tumor types Combinations of PD-1 + TIGIT inhibitors have potential to expand checkpoint inhibitor utilization to new tumors and lines of therapy REDWOOD CITY, Calif., and SHANGHAI, China, Jan. 10, 2022 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (("Coherus", NASDAQ: CHRS ) and Shanghai Junshi Biosciences Co., Ltd. ("Junshi Biosciences", HKEX: 1877; SSE: 688180) today announced that Coherus has initiated the process to exercise its option to license JS006, Junshi Biosciences'' TIGIT-targeted antibody, in the United States and Canada, expanding the companies'' 2021 immuno-oncology collaboration agreement. Coherus will pay Junshi Biosciences $35 million upfront, up to $255 million in development regulatory and sales milestones, and an 18% royalty on net product revenue, subject to terms and conditions agreed between the parties. Closing of the transaction is expected to follow receipt of any applicable regulatory clearances.

REDWOOD CITY, Calif., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that senior management will present at the virtual 40th Annual J.P. Mor

Coherus BioSciences Inc. (NASDAQ:CHRS) concluded the trading at $17.78 on Thursday, December 23 with a fall of -0.56% from its closing price on previous day. Taking a look at stock we notice that its last check on previous day was $17.88 and 5Y monthly beta was reading 0.96 with its price kept floating in the Coherus BioSciences Inc. (CHRS) Is Worth A Look Now, Despite -19.97% Loss From High Read More »

REDWOOD CITY, Calif., Dec. 17, 2021 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (NASDAQ: CHRS ), today announced the addition of Theresa LaVallee, Ph.D. as its Chief Development Officer. Dr. LaVallee will serve as a member of the Company''s executive leadership team and oversee all regulatory matters and product development functions, reporting to Denny Lanfear, President and CEO of Coherus. "Theresa is a terrific addition to Coherus at a time when we are increasingly focused on our immuno-oncology pipeline, particularly combinations with toripalimab, our PD-1 inhibitor," said Mr. Lanfear. "She is a seasoned executive with a proven track record of success in the end-to-end discovery and development of drugs and diagnostics for cancer. With her scientific and regulatory expertise, she will play a critical role in the growth of our immuno-oncology development capabilities." "Coherus'' lead immuno-oncology asset, toripalimab, is establishing a compelling clinical profile in late-stage trials.

REDWOOD CITY, Calif., Dec. 17, 2021 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq: CHRS), today announced the addition of Theresa LaVallee, Ph.D. as its Chief Development Officer. Dr. LaVallee will serve as a member of the Companys executive leadership team and oversee all regulatory matters and product development functions, reporting to Denny Lanfear, President and CEO of Coherus.

H.C. Wainwright Stick to Their Buy Rating for Coherus Biosciences